Novo Nordisk A/S

( )
NVO PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson 4.17%139.760.7%$2263.93m
PFEPfizer Inc. 2.65%34.530.9%$1462.96m
MRKMerck & Co., Inc. 5.36%80.340.7%$1347.05m
ABBVAbbVie, Inc. 2.99%75.562.3%$1227.94m
BMYBristol-Myers Squibb Co. 3.98%57.741.0%$1157.01m
LLYEli Lilly & Co. 1.17%141.301.1%$872.78m
NVSNovartis AG 2.58%85.800.2%$305.75m
AZNAstraZeneca Plc 0.77%44.301.2%$301.56m
GSKGlaxoSmithKline Plc 2.10%37.920.2%$258.31m
SNYSanofi 2.88%46.120.2%$176.94m
NVONovo Nordisk A/S 1.40%60.680.1%$171.78m
FTSVForty Seven, Inc. 0.05%95.510.0%$152.45m
BHCBausch Health Cos., Inc. 9.77%14.610.0%$97.57m
RGENRepligen Corp. 2.55%100.717.1%$73.73m
RETAReata Pharmaceuticals, Inc. 7.32%138.293.4%$66.79m

Company Profile

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.